title: Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia.
authors.forename: Q D
authors.initials: QD
authors.lastname: Nguyen
authors.forename: S
authors.initials: S
authors.lastname: Shah
authors.forename: S
authors.initials: S
authors.lastname: Tatlipinar
authors.forename: D V
authors.initials: DV
authors.lastname: Do
authors.forename: E V
authors.initials: EV
authors.lastname: Anden
authors.forename: P A
authors.initials: PA
authors.lastname: Campochiaro
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D047728:Myopia, Degenerative / Q000150:complications*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab